Shattuck Labs (STTK)
Develops DR3-blocking antibodies for inflammatory and immune-mediated diseases.
$6.71
Pre-market−0.20 (−2.89%)
At close$6.91(+0.58%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions83 holders · as of Mar 31, 2026 | 55.87% | 56.07M shares | |
| Insiders7 holders · as of Jul 7, 2026 | 1.13% | 1.13M shares | |
| Strategic holders1 holder · as of Jun 17, 2026 | 4.98% | 5.00M shares | |
| Otherremainder | 38.02% | 38.16M shares |
100.36M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (100.36M in the company's Sep 3, 2026 report, 90.37M elsewhere); stakes use the report.
Institutions13F, as of Mar 31, 2026
83 holders · 56.07M shares · 25 new positions · 57 increased · 13 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 9.87M | 9.83% | +8.51M | May 15, 2026 |
| Orbimed Advisors LLC | 6.31M | 6.28% | 0 | May 15, 2026 |
| Redmile Group, LLC | 5.54M | 5.52% | 0 | May 15, 2026 |
| Prosight Management, LP | 5.00M | 4.99% | +2.62M | May 15, 2026 |
| Adage Capital Partners GP, L.L.C. | 4.64M | 4.63% | −1.66M | May 15, 2026 |
| Nextbio Capital Management LP | 3.15M | 3.14% | 0 | May 14, 2026 |
| Vanguard Capital Management LLC | 2.28M | 2.27% | +2.28Mnew | May 15, 2026 |
| Price T Rowe Associates Inc /MD/ | 1.78M | 1.78% | −143.4K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13.80% | 9.87M | 13G | May 15, 2026 ↗ |
| Orbimed Advisors LLCincl. OrbiMed Capital GP IX LLC, OrbiMed Genesis GP LLC | 9.99% | 9.02M | 13D | Jun 15, 2026 ↗ |
| Redmile Group, LLCincl. Redmile Biopharma Investments II, L.P., Jeremy C. Green | 9.90% | 10.02M | 13D | Jul 17, 2026 ↗ |
| Prosight Management, LP | 9.90% | 6.54M | 13G | Nov 13, 2025 ↗ |
| Adage Capital Management, L.P. | 9.79% | 4.68M | 13G | Feb 12, 2025 ↗ |
| Deep Track Capital, LP | 5.17% | 5.00M | 13G | Jun 17, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 2, 2026 | Abhinav A. Shuklaofficer: Chief Technical Officer | Sale | 410 | $7.01 | 86,380 |
| Jun 30, 2026 | Arundathy N. Panditeofficer: Chief Medical Officer | Sale | 30,000 | $7.01 | 136,219 |
| Jun 30, 2026 | Abhinav A. Shuklaofficer: Chief Technical Officer | Sale | 23,365 | $7.08 | 86,380 |
| Jul 1, 2026 | Abhinav A. Shuklaofficer: Chief Technical Officer | Sale | 100 | $7.07 | 86,380 |
| Jun 11, 2026 | Orbimed Advisors LLCdirector | Purchase · 2 lots | 1,250,000 | $0.0001 | 26,519,541 |
| Jun 11, 2026 | Mona Ashiyadirector | Purchase · 2 lots | 1,250,000 | $0.0001 | 26,519,541 |
| Jun 9, 2026 | Clay B. Siegalldirector | Purchase | 62,500 | $4.00 | 318,608 |
| May 12, 2026 | Arundathy N. Panditeofficer: Chief Medical Officer | Sale | 30,000 | $6.61 | 166,219 |
| May 12, 2026 | Abhinav A. Shuklaofficer: Chief Technical Officer | Sale | 2,032 | $7.01 | 81,258 |
CongressHouse and Senate disclosures
Not reported.